Faced with the eruption of the coronavirus pandemic, individual academic and clinical laboratories, funding agencies, and entire governments are intensifying efforts to develop and deploy safe and effective vaccines and/or antiviral medications. Whereas vaccines may become available within a year or so, development and approval of a brand new drug will, most likely, require a significantly longer time, not relevant to the current exigency. Accordingly, much of the ongoing effort has been focused on drugs that are already approved and could be re-purposed against COVID-19. In particular, first reports have been emerging in the scientific literature that chloroquine (CQ) and hydroxychloroquine (HCQ) -vintage drugs to treat malaria as well as some autoimmune diseases -efficiently inhibit SARS-CoV-2 infection in vitro by slowing down entry of viruses into the cell and by blocking their transport from early endosomes to endolysosomes , causing noticeable enlargement of the former and affecting the pH levels within the endolysosomal tract. Since HCQ is less toxic than CQ and given current lack of viable alternatives, the use of this relatively safe drug against the COVID-19 pandemic appears imminent, even in the absence of comprehensive clinical data -in fact, Novartis has just announced 7 that it intends to donate for experimental treatments up to 130 million 200 mg doses by the end of May, 2020, including all of its current stock 7 . Still, should HCQ prove effective, the demand might soon surpass supply. Moreover, the key synthetic methods leading to HCQ are very often protected by patents, including some very recent ones (see Figure ), and we cannot exclude the possibility that monetary, corporate interests would interfere with humanitarian inspirations. In addition, the failure of the worldwide logistics and supply chains that accompanies COVID-19 pandemic might render some key substrates temporarily unavailable, in effect delaying execution of the proven synthetic routes and calling for alternative synthetic solutions. Anticipating such complications, we harnessed the power of Chematica -an experimentally-tested 9,10 platform for computer-assisted retrosynthesis of both known and unknown target molecules -to design syntheses of HCQ that would (1) commence from various inexpensive and popular starting materials (so that the syntheses minimize the abovementioned supply problems); (2) circumvent patented methodologies whenever possible ; and (3) minimize the use of expensive methodologies and/or reagents. In the following, we briefly outline the computational methods underlying Chematica's retrosynthetic searches, summarize the known syntheses of HCQ, and then describe novel ones identified by Chematica to meet conditions (1)-(3). We hope that at least some of these syntheses can become useful in streamlining economically feasible and widely accessible production of HCQ. We remain open to performingon a pro bono basis -similar synthetic analyses for organizations considering production and unrestricted (both geographically and economically) distribution of other potential anti-COVID-19 agents, should such agents become available in the near future.